News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
‘Hitch-hiking’ viral therapy deals a double blow to cancer
Scientists have shown how a promising viral therapy that delivers a double blow to cancer can sneak up on tumours undetected by hitching a ride on blood cells.
Abiraterone acetate shows success in earlier-stage prostate cancer patients
A large-scale international trial has shown that the ICR-discovered drug abiraterone acetate can benefit patients with earlier-stage prostate cancer, according to results being presented at the ASCO annual meeting today.
Prostate cancer drug shown to extend life and improve quality of life
The drug enzalutamide has been shown to extend life for men with advanced prostate cancer and offers improved quality of life, according to new data from a Phase III clinical trial jointly led by the ICR and The Royal Marsden.
Breakthrough treatments for cancer patients are presented at ASCO
Clinicians and scientist from The Royal Marsden and the ICR will be presenting new pioneering research at the American Society of Clinical Oncology Annual Meeting.
Gene link to higher rates of bowel cancer in men
Scientists have shown for the first time that one of the sex chromosomes is involved in the development of a cancer that can afflict both genders, according to a study in Nature Genetics.
New test may reduce chemotherapy use in breast cancer
A new test called IHC4 that is being considered for use on the NHS could identify patients at such low risk of their breast cancer returning after surgery that they may be spared chemotherapy.
Drug developers welcome NICE guidance on abiraterone
The Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust have welcomed the publication of guidance from the National Institute for Health and Clinical Excellence (NICE) recommending that patients with advanced prostate cancer receive abiraterone acetate on the NHS
New understanding of breast cancer genes and mutations
Researchers have identified nine new genes that drive the development of breast cancer, taking the tally associated with this type of cancer to 40. The study, which involved ICR scientists, published in the journal Nature.
Leading prostate cancer researchers elected to Academy of Medical Sciences
Two eminent researchers from the ICR and The Royal Marsden have been elected to the Academy of Medical Sciences in recognition of their efforts to defeat prostate cancer.
Next-generation “epigenetic” cancer pill shown to be safe
Scientists have shown that a brand new type of cancer pill that exploits the emerging field of epigenetics is safe for human use, according to a Phase I trial reported today in Clinical Cancer Research.
Combining prostate cancer drugs could delay drug resistance, study finds
Combing two new prostate cancer drugs could increase the number of men who respond to treatment and the length of time they benefit, research led by the ICR has shown.
Scientists find DNA variants linked with childhood kidney cancer
An international collaboration led by The Institute of Cancer Research (ICR) has found variations of the genetic code in two regions of the genome that increase the risk of developing Wilms tumour.
